Publication detail

Simulation of airway deposition distribution of an aerosol drug in COPD patients

FARKAS, Á. LÍZAL, F. JEDELSKÝ, J. ELCNER, J. HORVÁTH, A. JÍCHA, M.

Original Title

Simulation of airway deposition distribution of an aerosol drug in COPD patients

Type

article in a collection out of WoS and Scopus

Language

English

Original Abstract

Medical aerosols are key elements of current chronic obstructive pulmonary disease (COPD) therapy. Therapeutic effects are conditioned by the delivery of the right amount of medication to the right place within the airways, that is, to the drug receptors. Deposition of the inhaled drugs is sensitive to the breathing pattern of the patients which is also connected with the patient’s disease severity. The objective of this work was to measure the realistic inhalation profiles of mild, moderate and severe COPD patients, simulate the deposition patterns of Symbicort® Turbuhaler® dry powder drug and compare them to similar patterns of healthy control subjects. For this purpose a stochastic airway deposition model was applied. Our results revealed that the mount of drug depositing within the lungs correlates with the degree of disease severity. While drug deposition fraction in the lungs of mild COPD patients compares with that of healthy subjects (28% versus 31%), lung deposition fraction characteristic of severe COPD patients is lower by a factor of almost two (about 17%). Deposition fraction of moderate COPD patients was in-between (23%). This implies that for the same inhaler dosage severe COPD patients receive a significantly lower lung dose, though they would need more.

Keywords

Lungs, COPD, Aerosols, Simulation

Authors

FARKAS, Á.; LÍZAL, F.; JEDELSKÝ, J.; ELCNER, J.; HORVÁTH, A.; JÍCHA, M.

Released

13. 11. 2018

Pages from

136

Pages to

139

Pages count

4

BibTex

@inproceedings{BUT152125,
  author="Árpád {Farkas} and František {Lízal} and Jan {Jedelský} and Jakub {Elcner} and Alpár {Horváth} and Miroslav {Jícha}",
  title="Simulation of airway deposition distribution of an aerosol drug in COPD patients",
  year="2018",
  pages="136--139"
}